← Back to Analyst Consensus 
AKBA Buy
Akebia Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 15, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Sep 8, 2026 | WestPark Capital | initiate | — → Buy | — | 51% |
| Aug 7, 2026 | Leerink Partners | downgrade | Outperform → Market Perform | — | 50% |
| Jul 1, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 7, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Feb 25, 2026 | BTIG | maintain | Buy → Buy | $4 | 52% |
| Feb 6, 2026 | Piper Sandler | maintain | Overweight → Overweight | $4 | 54% |
| Feb 6, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Dec 2, 2025 | BTIG | reiterate | Buy → Buy | $5 | 52% |
| Dec 2, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Oct 30, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| Oct 29, 2025 | BTIG | maintain | Buy → Buy | $5 | 52% |
| Apr 28, 2025 | Leerink Partners | initiate | — → Outperform | $7 | 50% |
| Apr 4, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Apr 1, 2025 | Jefferies | initiate | — → Buy | $6 | 52% |
| Mar 14, 2025 | Piper Sandler | maintain | Overweight → Overweight | $6 | 54% |
| Mar 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Jan 23, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Jan 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Oct 23, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Oct 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Oct 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Sep 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7.5 | 44% |
| Aug 12, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $7.5 | 44% |
| Mar 28, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| Mar 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Nov 17, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $5 | 44% |
| Sep 27, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $3.75 | 44% |
| Aug 28, 2023 | HC Wainwright & Co. | upgrade | Neutral → Buy | $3.75 | 44% |
| Aug 11, 2023 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $2 | 44% |
| Jun 21, 2023 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $2 | 44% |
| Jun 14, 2023 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $2 | 44% |
| Jun 2, 2023 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $2 | 44% |
| May 31, 2023 | Piper Sandler | upgrade | Neutral → Overweight | $4 | 54% |
| May 30, 2023 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $2 | 44% |
| May 26, 2023 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $2 | 44% |
| May 9, 2023 | Needham | reiterate | — → Neutral | $2 | 50% |
| Apr 26, 2023 | HC Wainwright & Co. | maintain | — → Neutral | $2 | 44% |
| Mar 31, 2023 | HC Wainwright & Co. | reiterate | — → Neutral | $1.25 | 44% |
| Mar 10, 2023 | HC Wainwright & Co. | reiterate | — → Neutral | $1.25 | 44% |
| Feb 22, 2023 | HC Wainwright & Co. | maintain | — → Neutral | $1.25 | 44% |
| May 16, 2022 | HC Wainwright & Co. | maintain | — → Neutral | $1.25 | 44% |
| Mar 31, 2022 | HC Wainwright & Co. | downgrade | Buy → Neutral | $2 | 44% |
| Mar 31, 2022 | Needham | downgrade | Buy → Hold | $0 | 50% |
| Mar 31, 2022 | Mizuho | downgrade | Buy → Neutral | $2 | 52% |
| Mar 31, 2022 | Piper Sandler | downgrade | Overweight → Neutral | $2 | 54% |
| Nov 11, 2021 | HC Wainwright & Co. | maintain | — → Buy | $10 | 44% |
| Mar 8, 2021 | Cantor Fitzgerald | initiate | — → Overweight | $8 | 50% |
| Mar 8, 2021 | HC Wainwright & Co. | maintain | — → Buy | $6 | 44% |
| Jan 29, 2021 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
Price Target Trend
Jun 27, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days